Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,347 result(s) found. Displaying page 1,126 of 2,218.
    «« First « Previous 1122  1123  1124  1125  1126  1127  1128  1129  1130  Next» Last»»
    EudraCT Number: 2004-001175-19 Sponsor Protocol Number: 102247 Start Date*: 2004-08-24
    Sponsor Name:GlaxoSmithKline
    Full Title: A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenua...
    Medical condition: Two-dose immunization according to 0, 1 or 2-month schedule against rotavirus disease in healthy infants aged 6 to 14 weeks at the time of the first dose. Rotavirus infection.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000428-18 Sponsor Protocol Number: SP790 Start Date*: 2005-06-08
    Sponsor Name:Schwarz Biosciences GmbH
    Full Title: A mulit-center, randomized, double-blind, placebo-controlled, four-arm parallel group trial to investigate the efficacy and safety of three different transdermal doses of rotigotine in subjects wit...
    Medical condition: Restless Leg's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    7.0 10058920 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) SE (Completed) FI (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003290-25 Sponsor Protocol Number: A1481239 Start Date*: 2005-12-23
    Sponsor Name:Pfizer AB
    Full Title: A multicenter, double-blind placebo controlled, fixed dose study with an open-label, flexible dose phase to assess the efficacy of Sildenafil Citrate in providing a better sexual experience includi...
    Medical condition: Erectile Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061461 LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000039-73 Sponsor Protocol Number: CSPP100A2327 Start Date*: 2005-07-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An 8-week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg and 300 mg) administer...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000354-22 Sponsor Protocol Number: A3841029 Start Date*: 2004-12-06
    Sponsor Name:Pfizer Healthcare Ireland
    Full Title: An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine –Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL II Study)
    Medical condition: Concurrent hypertension (ICD code 80011/MedDRA: coded under preferred term "vascular system order", code 10020772) and dyslipidaemia (ICD code 89212/MedDRA: coded under preferred term "metabolism a...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) AT (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000774-31 Sponsor Protocol Number: E7070-E044-213 Start Date*: 2005-10-12
    Sponsor Name:Eisai Limited
    Full Title: An open-label, randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast can...
    Medical condition: Treatment of metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004803-39 Sponsor Protocol Number: SA-NXY-0007 Start Date*: 2005-10-07
    Sponsor Name:AstraZeneca AB
    Full Title: SAINT II (Stroke - Acute Ischemic - NXY Treatment) A double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous ...
    Medical condition: Acute ischemic stroke.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SK (Completed) ES (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000158-61 Sponsor Protocol Number: CXA30009 Start Date*: 2005-07-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10039073 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) AT (Completed) HU (Completed) ES (Completed) IE (Completed) EE (Prematurely Ended) LV (Completed) CZ (Completed) IT (Completed) LT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004984-32 Sponsor Protocol Number: NKF100096 Start Date*: 2005-06-10
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depres...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000745-37 Sponsor Protocol Number: AC-052-413 Start Date*: 2004-10-11
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Uncontrolled extension trial to protocol AC-052-406 to evaluate the long-term effects of bosentan therapy in patients with pulmonary arterial hypertension related to connective tissue disease (TRUS...
    Medical condition: Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary arterial pressure and pulmonary vascular resistance leading to right ventricular failure. PAH is a serious complication...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023111-34 Sponsor Protocol Number: SG1/001/10 Start Date*: 2011-07-18
    Sponsor Name:Oxford BioMedica (UK) Ltd
    Full Title: A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration.
    Medical condition: Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Not Authorised) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-004465-15 Sponsor Protocol Number: Study No. 957 Start Date*: 2005-04-05
    Sponsor Name:Biotest AG
    Full Title: A multicentre, open, prospective study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT681 in patients wi...
    Medical condition: primary immunodeficiency syndrome as congenital agammaglobulinaemia or hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiencies, Wiskott Aldrich syndrome
    Disease: Version SOC Term Classification Code Term Level
    7.0 10036700 HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-005181-57 Sponsor Protocol Number: GWT12395-2017 Start Date*: 2018-05-07
    Sponsor Name:GWT-TUD GmbH
    Full Title: A randomized, placebo-controlled, double-blind study to scrutinize the efficacy of Secukinumab in patients with moderate to severe atopic dermatitis
    Medical condition: Moderate to serve atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004591-35 Sponsor Protocol Number: ADVL1211 Start Date*: 2018-12-14
    Sponsor Name:National Cancer Institute Cancer Therapy Evaluation Program (NCI/CTEP)
    Full Title: A PHASE 1 STUDY OF XL184 (CABOZANTINIB, IND# 116059) IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
    Medical condition: Patients with relapsed or refractory solid tumors including CNS tumors and malignant melanoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-006287-50 Sponsor Protocol Number: EMAOS Start Date*: 2015-04-01
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: Phase III comparative clinical trial to evaluate the efficacy of amniotic membrane extract for the treatment of severe dry eye disease, in comparison with autologous serum eyedrops.
    Medical condition: Severe Dry Eye Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10013778 Dry eyes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001682-33 Sponsor Protocol Number: GB001-2101 Start Date*: 2019-09-09
    Sponsor Name:GB001, Inc.
    Full Title: A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the effect of GB001 in patients with chronic rhinosinusitis with or without nasal polyps
    Medical condition: Chronic Rhinosinusitis with or without Nasal Polyps
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10071399 Chronic eosinophilic rhinosinusitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-002943-40 Sponsor Protocol Number: ALN-CC5-003 Start Date*: 2016-11-21
    Sponsor Name:Alnylam Pharmaceuticals Inc
    Full Title: A Phase 2, Open-label, Single Dose, Study of Subcutaneously Administered ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria who are Inadequate Responders to Eculizumab
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002913-12 Sponsor Protocol Number: M12-895 Start Date*: 2012-05-15
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplati...
    Medical condition: BRCA1 or BRCA2 mutation metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) DK (Completed) SK (Completed) FI (Completed) SE (Completed) BE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003652-52 Sponsor Protocol Number: 991 Start Date*: 2016-09-29
    Sponsor Name:Biotest AG
    Full Title: An open label, prospective, multicenter study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT595 as repl...
    Medical condition: Replacement therapy in patients with primary immunodeficiency disease (PID)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10064859 Primary immunodeficiency syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000928-18 Sponsor Protocol Number: PROMESA Start Date*: 2013-11-21
    Sponsor Name:Hospital of the Ludwig-Maximilians-University of Munich
    Full Title: Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atr...
    Medical condition: Progression of patients with Multiple System Atrophy (MSA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1122  1123  1124  1125  1126  1127  1128  1129  1130  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 12:53:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA